Healthtech & Wellness VC Funds

A.Capital Ventures, co-founded by Ronny Conway and Ramu Arunachalam, focuses on providing strategic investments and support to early-stage startups. Based in the US, A.Capital is noted for its flexible investment approach, allowing startups to grow without significant dilution or stringent ownership thresholds. They prioritize high-potential sectors like AI, blockchain, and enterprise software. A.Capital's portfolio includes notable companies like Notion, Airbnb, and Coinbase, showcasing their strength in backing transformative technologies. The firm offers more than just capital; they provide valuable connections, world-class advice, and access to top talent, thanks to their partners' extensive experience at Google and other tech giants. A.Capital avoids traditional board seat requirements, instead fostering a collaborative partnership with founders. This unique model has enabled startups to scale effectively, leveraging the firm's resources and networks without compromising control. Entrepreneurs can approach A.Capital through their network of referrals or by directly engaging with their team during industry events. With a clear focus on building the future through innovation and a hands-on investment strategy, A.Capital Ventures stands out as a pivotal supporter of groundbreaking startups across various tech-driven industries​.

A Partners Capital is a global outsourced CIO (Chief Investment Officer) firm that provides tailored investment solutions to endowments, foundations, private clients, and institutions. Established in 2001, the firm is headquartered in London with additional offices in Boston, San Francisco, Singapore, Paris, and Hong Kong​. A Partners Capital focuses on alternative investments, including private equity, real estate, and hedge funds, seeking to deliver superior long-term returns through a rigorous, research-driven approach. Their investment philosophy emphasizes diversification, sustainability, and long-term value creation, utilizing their extensive global network and deep industry expertise. The firm provides clients with bespoke investment strategies that are aligned with their financial objectives and risk tolerance. A Partners Capital also manages private market mandates, offering opportunities in co-investments and direct investments across multiple sectors​. With a commitment to transparency and strong governance, A Partners Capital builds enduring partnerships with clients, helping them navigate complex market environments while maximizing returns.

A-Star is a dynamic investment firm that excels in scaling early-stage companies with significant growth potential. The firm’s strategy revolves around providing both capital and strategic support, ensuring that startups can transition from promising ideas to thriving businesses. A-Star is deeply committed to fostering long-term partnerships, taking a hands-on approach in guiding companies through critical growth stages. The firm’s team boasts a wealth of experience in entrepreneurship, finance, and venture capital, enabling them to identify and nurture innovative businesses across a wide range of sectors. This expertise allows A-Star to build a diverse portfolio of transformative companies, each poised to make a substantial impact in their respective industries. With a keen focus on sustainable growth and long-term success, A-Star partners with entrepreneurs who share a vision for innovation and excellence. Through their dedicated involvement, A-Star helps these companies navigate the complexities of scaling, providing the necessary tools and resources to achieve market leadership. The firm’s approach is characterized by its emphasis on collaboration and its commitment to the sustained success of its portfolio companies. By leveraging their extensive network and industry insights, A-Star not only supports the growth of individual companies but also contributes to the broader entrepreneurial ecosystem. Their mission is to empower visionary founders and turn high-potential startups into market-leading enterprises, driving meaningful change and creating lasting value.

AAF Management Ltd., founded in 2016 and headquartered in Washington, D.C., is a prominent early-stage venture capital firm. The firm focuses on pre-seed, seed, and Series A stage technology companies in North America, with particular emphasis on sectors such as fintech, healthcare, consumer tech, enterprise software, and deep tech. AAF Management has an impressive portfolio of over 120 venture-backed companies. Notable investments include Robinhood, Didi, Savage X Fenty, StockX, Figure, Reddit, Current, Synthego, Jasper, and Drata. The firm has also celebrated significant exits, such as CrowdStrike (NASDAQ: CRWD), TruOptik (acquired by TransUnion), Even Financial (acquired by MoneyLion), Prodigy (acquired by Upstart), Portfolium (acquired by Instructure), and HeyDoctor (acquired by GoodRx). The firm is backed by over 95 limited partners, including family offices, royal families, C-level executives, and hedge fund managers from the US, Europe, and MENA regions. AAF Management prides itself on its strategic value-add, leveraging a vast network to support its portfolio companies and emerging managers globally.

Aavishkaar Capital is a pioneering Indian impact investing firm founded in 2001, one of the first to apply a venture capital approach to early-growth enterprises in overlooked and challenging geographies across the Global South. Based in Mumbai and part of the broader Aavishkaar Group — which also includes microfinance institution Arohan, NBFC Ashv, advisory platform Intellecap, and the Aavishkaar Foundation — the firm manages $1.45 billion in AUM across eight funds. With over 80 portfolio companies and approximately 50 exits, Aavishkaar has built one of the most extensive impact investment track records in Asia. The firm leads rounds with checks of $5 million to $25 million at Series A through late stage, investing in three core sectors: financial inclusion, food and agriculture, and essential services. Its geographic mandate has expanded from India to include Emerging Asia and Sub-Saharan Africa, backing companies that create livelihoods, reduce household vulnerabilities, and improve access to essential products and services while delivering commercial returns. Aavishkaar's 2016 organizational restructuring formalized the Aavishkaar Group structure, enabling each member institution to pursue its development mandate at scale while sharing research, networks, and operational infrastructure. The firm's quarter-century of investing in underserved markets has informed a rigorous due diligence process that evaluates both financial sustainability and measurable social impact — a dual mandate that has attracted institutional capital from development finance institutions and international impact investors.

Abbott Ventures is the corporate venture capital arm of Abbott Laboratories, the global healthcare company, founded in 2004 and based in Abbott Park, Illinois. The firm focuses exclusively on emerging medical technologies including medical devices, diagnostics, drug delivery, and drug-device combinations that align with Abbott's strategic priorities across its core healthcare businesses. Unlike independent VC funds, Abbott Ventures targets investments where it sees the largest impact on Abbott's medical device divisions and can simultaneously create shareholder value while improving patient outcomes. Typical deal sizes range from $10 million to $50 million at Series B and later stages. The portfolio of 18 investments includes Bigfoot Biomedical, a diabetes management technology company, and Direct Flow Medical, which focused on structural heart disease — both reflecting Abbott's deep medical device and diagnostics expertise. Additional portfolio companies span the spectrum of medical technology, from monitoring equipment to therapeutic devices. Abbott Ventures provides portfolio companies with access to Abbott's global healthcare infrastructure: regulatory expertise built across decades of FDA and international approvals, clinical networks spanning hospitals and health systems worldwide, and commercial distribution channels reaching patients in more than 160 countries. This strategic positioning makes Abbott Ventures a particularly valuable partner for medical technology companies seeking both capital and an accelerated path to clinical adoption and commercial scale in the competitive medical devices market.

AbbVie Biotech Ventures — now operating as AbbVie Ventures — is the corporate venture arm of AbbVie, the global biopharmaceutical company. Founded in 2009 as Abbott Biotech Ventures and based in North Chicago, Illinois, with team members across Cambridge, San Francisco, and Oxford, the firm focuses exclusively on novel, transformational therapeutics at discovery and pre-clinical stages. Led by Vice President Adam Houghton and a four-person team, AbbVie Ventures has built a portfolio of 96 investments across oncology, immunology, neuroscience, eye care, and aesthetics — the same therapeutic areas in which AbbVie has established global commercial and scientific leadership. The firm invests at Seed and Series A stages with checks of $3 million to $30 million, backing companies including DISCO Pharmaceuticals, Zag Bio, and Soufflé Therapeutics across drug discovery, drug delivery, and therapeutic devices. The portfolio reflects a deliberate focus on the earliest translational science, where AbbVie's deep biological expertise can add the most differentiated value to founders navigating target validation and preclinical development. AbbVie Ventures gives portfolio companies access to AbbVie's scientific infrastructure: world-class drug discovery platforms, development and regulatory expertise across multiple global markets, and commercial capabilities in immunology and oncology built over decades. This combination of early-stage risk appetite with large-pharma scientific resources positions AbbVie Ventures as a differentiated partner for founders working at the frontier of biopharmaceutical innovation.

Abenteuer Ventures is a Menlo Park-based venture firm that focuses on angel investments in emerging technologies across sectors like tech, bio-science, and space exploration. The firm actively invests in early-stage startups, emphasizing innovative solutions that have the potential to make a significant impact on industries and society. Abenteuer Ventures collaborates with various syndicates, including notable names like Flight VC and Hack VC, giving it access to a wide range of deals. Their portfolio includes companies across a diverse array of industries, such as Akash Systems, which pioneers satellite communications technology, DroneSeed, offering drone-based reforestation solutions, and BillionToOne, which develops genetic testing technologies. Abenteuer Ventures typically invests in companies that align with its mission to leverage technology for transformative change, supporting everything from smart robotics to advanced medical devices. The firm’s approach centers on helping startups navigate early challenges while providing access to a network of strategic partners and investors. Their investments usually focus on seed-stage rounds, and they continue to support portfolio companies through follow-on funding and expert guidance.

Aberdare Ventures is a San Francisco-based venture capital firm founded in 1999 and focused exclusively on transformational healthcare companies. Led by Managing Partner Paul Klingenstein and a three-partner team, the firm has built a portfolio of 101 investments spanning seed through later stage, making it one of the most active and longest-tenured healthcare-focused VCs in the United States. Aberdare also deploys private equity and grants capital to the healthcare sector, reflecting a broad commitment to the ecosystem rather than a narrow venture mandate. The firm invests $1 million to $15 million per round in companies that apply biological, engineering, and information technologies to make healthcare more efficient, less costly, and smarter. The portfolio skews heavily toward health technology and biotech, with 55 and 20 investments respectively, supplemented by software and data analytics companies that serve the healthcare industry. Aberdare leads rounds across its investment spectrum. Aberdare Ventures' quarter-century of healthcare specialization has produced deep pattern recognition in a sector where regulatory complexity, long development timelines, and reimbursement dynamics make generalist investors less equipped to evaluate risk. The firm's longevity and focused mandate allow it to bring experienced judgment to founders navigating the clinical development, FDA approval, and commercialization processes that define success in medical technology. Its extensive portfolio and active board involvement provide portfolio companies with a network of peers, advisors, and potential partners across the healthcare landscape.

Abies Ventures is a Tokyo-based venture capital firm that specializes in deep tech investments, aiming to tackle global issues like environmental degradation and food shortages through science and advanced technologies. Established in 2017, the firm focuses on early-stage companies with innovative solutions in areas such as AI, robotics, quantum computing, and biotech. Their portfolio includes cutting-edge startups like Synspective, Telexistence, and Mighty Buildings, reflecting their commitment to building sustainable, tech-driven solutions. Abies Ventures leverages its strong global network, partnering with large corporations, research institutes, and government agencies to help startups scale internationally. The fund is led by experienced venture founders like Fuyuki Yamaguchi and Sota Nagano, who bring extensive expertise in venture investment and scaling companies across Japan and the U.S. Their investment strategy centers on fostering deep tech companies with high impact potential, particularly in areas where finance, technology, and market dynamics may not always align. Abies Ventures helps bridge these gaps by providing strategic advice and connecting startups with key players to enhance their growth trajectory​.

Abingworth, founded in 1973, is a transatlantic life sciences investment firm with a robust portfolio and a strategic focus on turning innovative science into transformative medical treatments. With offices in London, Boston, and San Francisco, Abingworth has invested in over 179 companies, resulting in 73 IPOs and 46 M&As. The firm operates across three main investment stages: seed and early-stage, development stage, and clinical co-development, and typically invests between $500,000 to $2 million in initial rounds, supporting portfolio companies through subsequent funding stages. Notable investments include Adaptate Biotherapeutics, Jasper, and Tizona Therapeutics. Abingworth's team, led by Managing Partners Tim Haines and Kurt von Emster, brings decades of experience in life sciences and venture capital. The firm is deeply embedded in key biotech hubs, facilitating productive interactions with entrepreneurs and access to top-tier scientific talent. The firm emphasizes long-term partnerships, providing not just capital but also strategic guidance in areas such as clinical development, regulatory approval, and commercialization. Abingworth's recent integration with Carlyle Group underscores its commitment to expanding its impact in the global healthcare investment ecosystem. Startups seeking investment from Abingworth should have groundbreaking science with the potential to materially improve patient outcomes. The firm values deep industry expertise, strong leadership, and a clear path to transformative impact.

Able Partners, founded in 2016 and based in New York City, is a venture capital firm that focuses on investing in early-stage companies aiming to improve daily lives through health and wellness. The firm is known for its support of passionate entrepreneurs and inspiring brands across various industries including consumer products, health tech, and wellness. Their diverse portfolio includes investments in companies such as Clare, a direct-to-consumer paint company; Alto Neuroscience, a company focused on precision psychiatry; Little Otter, a mental health service for children and families; and Kindred, a network for professional caregivers. Other notable investments are Beam Impact, Vivvi, and Capable Health. Able Partners has made over 60 investments and has achieved multiple successful exits. Key exits include Alto Neuroscience, Stretch*d, and Capable Health, showcasing their ability to support companies from early stages to successful outcomes. The firm is led by co-founders Lisa Blau and Amanda Eilian, who bring extensive experience in consumer-focused investments and entrepreneurship. Their investment strategy emphasizes not only providing capital but also leveraging their extensive networks and expertise to help portfolio companies achieve their full potential.

ABS Ventures is a Waltham, Massachusetts-based mid-stage venture capital firm with a history dating to 1982, built around more than 25 years of helping exceptional management teams build industry-leading technology companies. The firm provides $5 million to $15 million of expansion and replacement capital through both primary and secondary direct investing strategies, deploying fresh growth capital, facilitating shareholder liquidity, and taking active board roles to drive value creation. The team of 10, including seven partners, invests across software, communications, and healthcare sectors. The portfolio of 70 investments includes Centric Software, an enterprise product lifecycle management platform; Melinta Therapeutics, a commercial-stage pharmaceutical company; and ClickSquared, a data-driven marketing software business. ABS Ventures leads rounds and its secondary investment capability distinguishes the firm — founders and existing shareholders can achieve liquidity without requiring an immediate exit, while ABS brings new strategic input alongside new capital. ABS Ventures' longevity reflects a disciplined investment philosophy centered on proven management teams, defensible market positions, and businesses with clear paths to significant exits. The firm's experience operating through multiple market cycles, from the dot-com era to the post-financial-crisis growth wave, has shaped a rigorous approach to company evaluation that prioritizes unit economics and management depth over growth narratives. Active board involvement ensures the firm's operational insights translate directly into portfolio company outcomes.

Abstract Ventures is a San Francisco-based VC firm founded in 2016, focusing on early-stage investments across biotech, consumer products, crypto, and enterprise frontier tech. The firm has gained a reputation for backing innovative and high-potential startups, with a portfolio that includes successes like Rippling and Material, the latter achieving unicorn status in 2022. Abstract Ventures primarily targets investments within the U.S., engaging in Seed and Series A rounds with typical check sizes ranging from $5 to $15 million. Their strategy blends flexibility with strategic partnerships, often co-investing with other VCs and leading rounds when they see transformative potential. Abstract is known for being founder-friendly, offering not just capital but also access to a wide network of industry experts, experienced entrepreneurs, and investors who can provide significant strategic value. In 2024, Abstract maintained a proactive stance, completing 16 new investments in companies such as Unify and Thirddimension.ai. The firm’s small yet powerful team is spearheaded by founder and General Partner Ramtin Naimi, who, along with four other partners, leverages years of investment experience and market insight from their base in San Francisco. Abstract Ventures advises founders to approach with a robust market strategy, proven product traction, and genuine storytelling. Rather than solely evaluating polished decks, the firm seeks authenticity and conviction in a startup’s vision. They primarily source deals through referrals and their network, emphasizing relationships and strategic alignment. With this approach, Abstract has carved out a distinctive presence in the early-stage VC landscape, empowering founders from idea to growth phase.

AC Ventures (ACV) is one of Southeast Asia's leading venture capital firms, headquartered in Jakarta, Indonesia, formed through the merger of Agaeti Venture Capital and Convergence Ventures. Founded in 2014 and co-led by Founder and Managing Partner Adrian Li and Co-Founder and Managing Partner Michael Soerijadji, the firm manages over $500 million in AUM across five funds. Fund V closed at $210 million in January 2024 with institutional LPs including the World Bank's IFC, investors from the United States, the Middle East, and North Asia, with over 90 percent institutional capital and more than 50 percent returning LPs. ACV invests $2 million to $5 million checks at early stage with potential follow-on up to $30 million for fast-growing portfolio companies, leading rounds across fintech, e-commerce, health technology, logistics, MSME enablement, and climate technology. The portfolio spans over 120 startups, with Fund V targeting 25 additional companies. The firm publishes an annual Indonesia Venture Capital Report in partnership with Bain and Company, providing comprehensive analysis of the country's startup ecosystem. ACV combines operating experience, deep industry knowledge, and local networks across Indonesia and the broader Southeast Asian region. The firm's hands-on approach helps entrepreneurs navigate the distinctive market dynamics of Indonesia's 270-million-person economy — from regulatory complexity to digital infrastructure gaps — while providing connections to ACV's extensive institutional LP base for follow-on funding and strategic partnerships.

Acadian Ventures is an early-stage VC firm that focuses on the future of work, helping to build technologies that make work better, more equitable, and productive. Founded in 2019 by Jason Corsello, Acadian Ventures targets pre-seed, seed, and early Series A companies globally, with an emphasis on work tech, particularly in areas like intelligent work applications, work infrastructure, and new regulatory and compliance solutions. The firm typically invests between $500K to $1M, often co-investing alongside other VCs, and prefers to "fast follow" rather than lead rounds. Their hands-on approach and deep industry expertise have garnered them a high reputation among founders, with portfolio companies such as TechWolf and Compa praising their value as advisors. Anchored by notable LPs like ServiceNow Ventures, Acadian recently closed its second fund, a $30M commitment, nearly tripling their assets under management. They pride themselves on being highly engaged investors, often joining company boards as observers to support founders​.

Accel is a renowned venture capital firm known for its strategic investments across various stages and sectors. Founded in 1983, Accel has played a pivotal role in the success of numerous high-profile companies. Some of its most notable investments include Facebook, Dropbox, Spotify, and Slack, showcasing its strength in identifying and backing transformative technology companies early on. The firm's investment strategy focuses on seed and Series A funding, ensuring deep engagement with startups from their inception. Accel emphasizes a collaborative approach, providing not just capital but also mentorship and strategic support to help entrepreneurs build market-defining businesses. This hands-on involvement has led Accel to lead investments in over 70% of its portfolio companies​. Accel operates globally, with key offices in Silicon Valley, London, and Bangalore, enabling it to tap into entrepreneurial talent worldwide. The firm has recently closed on several funds totaling $3.05 billion, aimed at supporting early-stage startups and growth rounds for more mature companies​​. In 2023, Accel made significant investments in companies like Blackpoint Cyber, Headway, and Cyera, reflecting its commitment to diverse sectors such as cybersecurity, mental health, and data protection​​. This broad sector focus, combined with a global investment perspective, positions Accel as a key player in the venture capital landscape, continuously driving innovation and supporting exceptional entrepreneurs around the world.

Accelerace is one of the most prominent pre-seed investors and startup accelerators in the Nordics, headquartered in Copenhagen. Founded in 2008, it has supported over 700 startups, including high-profile companies like Trustpilot, Templafy, and Coinify. Accelerace focuses on providing early-stage startups with capital and mentorship, investing up to 1 million DKK through standardized convertible loans. Their investment strategy targets industries such as fintech, healthtech, climatetech, SaaS, and e-commerce, helping startups build scalable solutions across these sectors. The firm’s accelerator program is a comprehensive seven-week initiative designed to prepare startups for fundraising, offering support with pitching, business development, and investor connections. Startups that graduate from the program gain access to the Accelerace Allstars community, a lifelong network of successful founders and industry experts who provide ongoing mentorship and strategic advice. Notable alumni include Donkey Republic and Actimo, which both achieved successful exits. With over 600 investments and a solid presence in Denmark, the Baltics, and other European regions, Accelerace continues to play a pivotal role in shaping the future of innovation in Europe.

Accelerate Blue Fund is a venture fund exclusively supporting startups spun out from the University of Michigan. With a focus on early-stage investments, the fund helps bridge the gap between initial seed funding and larger VC rounds for companies commercializing U-M intellectual property. Their portfolio spans innovative sectors like AI (MemryX), 3D printing (Ulendo), and healthtech (Auricle), positioning them at the forefront of tech and life sciences. Based in Ann Arbor, the fund provides hands-on mentorship, intellectual property support, and business guidance. Startups looking to engage should demonstrate strong market validation and customer insights.

Accelerate Venture Partners (AVP) is a Wichita, Kansas-based collaborative investor group founded in 2018, bringing together seasoned entrepreneurs, experienced investors, and angel-investment newcomers from diverse professional backgrounds to back early-stage, high-growth companies in Wichita and the broader US Midwest. Collectively, AVP members manage $1.7 billion in assets under management across their broader investment portfolios, reflecting significant professional depth within the network. AVP is structured differently from a traditional fund: individual investors make their own investment decisions on a deal-by-deal basis through purpose-built LLCs, rather than committing to a pooled vehicle. This format lowers the barrier to entry for new angel investors while giving experienced members the flexibility to participate selectively. The firm has made 17 portfolio investments, including Spinal Simplicity, an orthopedic device company, and Transportant, a logistics technology startup, with checks typically ranging from $100,000 to $1 million. AVP's core mission is to bring institutional-quality venture capital practice to non-traditional technology geographies in the US Midwest, where access to early-stage capital has historically been limited. By aggregating the experience, networks, and capital of members across diverse industries, AVP creates a collaborative investment community that supports Wichita-area founders at stages when they have few alternative sources of growth financing. The firm focuses on software, health technology, and transportation startups with clear regional or national growth potential.

Accelerated Ventures, based in San Mateo, California, is a venture capital firm focused on early-stage investments in tech and life sciences. The firm has built a diverse portfolio that includes notable companies such as Telesentry, Amnesty, and Diag-X. Their investment strategy emphasizes sectors like HealthTech and retail, aiming to support innovative startups in these industries. With a portfolio count of six companies, Accelerated Ventures provides funding and strategic guidance to help these startups scale and succeed. Key investments like Telesentry and Diag-X highlight their commitment to fostering growth in tech and healthcare. The firm is led by experienced professionals who bring a wealth of knowledge and expertise to their investment approach, ensuring that each portfolio company receives the support needed to thrive in competitive markets.

Accelerator Ventures is a San Francisco-based seed-stage venture capital fund founded in 2007 by Alexander Lloyd, who serves as Managing Partner. The firm specializes in early-stage technology companies typically raising less than $3 million, investing in fintech, health technology, and marketing technology. Over nearly two decades, the fund has backed 67 companies, with Lloyd personally participating in the first round of more than 100 startups. The firm leads rounds with checks around $2 million. Six of Lloyd's portfolio companies have gone public and 12 have been acquired for over $100 million each. Notable portfolio companies include Zappos, the online footwear retailer acquired by Amazon; Zynga, the social gaming company; Nutanix, the enterprise cloud computing firm; and Braze, the customer engagement platform. The firm counts one unicorn in its portfolio. Team member Chantalle Dumonceaux, who founded Womena — a women-focused angel fund — in 2013, joined in 2023 and extends the firm's reach into diverse founder networks. Accelerator Ventures supports founders beyond capital by assisting with financing strategy, customer introductions, and management team development. Lloyd's extensive network and pattern recognition from backing over 100 founders at the earliest stages enable the firm to provide substantive guidance during a company's most formative period. The fund's longevity and consistent seed-stage focus have produced a track record that reflects disciplined stage conviction rather than opportunistic investing across the venture lifecycle.

Access Bridge Ventures (ABV) is an early-stage venture capital fund with a focus on the Middle East, North Africa, and Pakistan (MENAP). With a fund size of $35 million, ABV looks to back startups in sectors like HealthTech, FinTech, SaaS, e-commerce, and marketplaces. Notable investments include Jawaker, Mumzworld, and Vezeeta. ABV often leads funding rounds and provides ongoing strategic support through its deep regional networks and operational expertise. The fund prioritizes capital-efficient, scalable ventures with strong market traction and innovative teams. While primarily investing in the MENAP region, they will occasionally consider startups from outside this geography if aligned with their sector interests. ABV aims for long-term growth and clear exit paths, and prefers startups with a distinct competitive advantage. Led by Issa Aghabi, a veteran in MENA venture capital, the ABV team includes experts like Imad Ghandour and Magellan Makhlouf, bringing extensive investment and operational experience. The team operates mainly out of Saudi Arabia and the UAE, actively sourcing deals and supporting their portfolio with hands-on engagement. Startups are encouraged to approach with a clear pitch that aligns with their strategic interests.

Access Medical Ventures is a North Haven, Connecticut-based venture capital firm founded in 2010, specializing in early-stage medical device and life sciences investments. The firm focuses primarily on interventional and therapeutic medical device companies, backed by a two-partner team that provides both capital and operational expertise to founders navigating the complex medical device regulatory and commercialization landscape. Checks range from $500,000 to $3 million at seed and Series A stages across the United States. The portfolio of 22 investments includes CartiHeal, a cartilage repair device company that was acquired on August 30, 2021; MinInvasive, a minimally invasive surgical device startup; and Revamp Medical, a therapeutic device company. Access Medical Ventures frequently co-invests alongside other healthcare-focused funds including Elron Ventures, a structure that allows portfolio companies to access deeper networks and follow-on capital from multiple institutional partners. Access Medical Ventures operates with a clear thesis: medical device innovation requires investors with the domain expertise to evaluate clinical evidence, regulatory pathways, and reimbursement dynamics alongside commercial potential. The firm's concentrated focus on interventional and therapeutic devices — rather than digital health or diagnostics — reflects a deliberate specialization in the hardware and materials science layer of medical technology. Founders benefit from direct engagement with partners who understand the specific challenges of FDA clearance, clinical trials, and hospital procurement that define the medical device commercialization path.

Access Venture Partners (AVP), based in Westminster, Colorado, has been a key player in the venture capital landscape since 1999. AVP focuses on early-stage investments, primarily in seed and Series A rounds, with particular interest in sectors such as cybersecurity, enterprise SaaS, and managed marketplaces. They look for startups with scalable business models and a clear path to significant market opportunities, often investing between $250k and $500k initially and maintaining reserves for follow-on support. The firm's portfolio boasts successful startups like Red Canary, LogRhythm, and Bonusly, reflecting their commitment to innovative technology companies in the Mountain West region and beyond. AVP values a hands-on approach, offering not just capital but also extensive operational support, leveraging over 100 combined years of expertise among its team members. Co-founded by Frank Mendicino III, who has a strong background in product development and sales, AVP's team includes Brian Wallace, an expert in venture capital finance and legal matters, and Eric Shu and Alex Houghtalin, who bring diverse experiences in strategy and entrepreneurship. Access Venture Partners prides itself on its founder-first philosophy, actively supporting the entrepreneurial community through mentorship, network introductions, and strategic guidance. This approach has enabled them to foster robust relationships with founders and help them navigate the critical early stages of growth

Accion Venture Lab is an early-stage venture fund focused on empowering inclusive fintech startups that serve underserved and low-income populations globally. Established as part of Accion, a nonprofit dedicated to financial inclusion, Venture Lab provides seed-first capital paired with extensive strategic and operational support to help startups scale and overcome early challenges. Their diverse portfolio features innovative companies like Apollo Agriculture, which offers tech-driven financing to smallholder farmers in Kenya and Zambia, and Bababos, an Indonesian platform that supports small-scale manufacturers with raw materials and financing solutions. With a geographic reach that spans Latin America, the Caribbean, sub-Saharan Africa, the Middle East, North Africa, Southeast Asia, and even parts of the U.S., Accion Venture Lab's commitment is global. The fund targets industries such as digital lending, insurtech, personal financial management, and MSME-focused solutions, identifying startups with a mission to address systemic barriers to financial access. Their strategy is unique in that they prefer being the first institutional investor, ensuring startups receive not just capital but high-touch mentorship and strategic guidance. In 2019, Accion Venture Lab boosted its support efforts by launching a $23 million fund aimed at deepening their investment into inclusive fintech. Their approach prioritizes not only financial backing but also leveraging their deep-rooted expertise in financial inclusion to provide hands-on operational assistance. The team is led by seasoned Managing Partners Amee Parbhoo and Rahil Rangwala, who bring years of experience in fintech, impact investing, and scaling social enterprises. Founders looking for support from Venture Lab should demonstrate impactful, scalable solutions with clear pathways to financial inclusion.

Accomplice Ventures, founded in 2015 and based in Boston, Massachusetts, is a prominent seed-led venture capital firm. The firm specializes in technology startups across various sectors including cybersecurity, eSports, data analytics, SMB software, emerging hardware platforms, and marketplaces. Notable investments by Accomplice include leading tech companies such as DraftKings, AngelList, Carbon Black, CoinList, Currencycloud, and FreshBooks. Their portfolio also features innovative firms like Hopper, Patreon, PillPack, SecurityScorecard, Veracode, and WHOOP. Accomplice has a significant track record of successful exits, with companies like Datadog, Snap, and DraftKings achieving substantial market presence and growth. Accomplice operates with a unique federated VC model, supporting initiatives such as the operator-angel movement through Spearhead and the blockchain sector via Accomplice Blockchain. They are also anchor LPs in numerous solo GP funds, reflecting their commitment to a diverse and dynamic investment strategy. The firm was initially part of Atlas Venture before the tech and life sciences groups split, with Accomplice focusing solely on tech investments. They have raised multiple funds, including $405 million for their final fund as of 2022, ensuring a robust financial backing for their portfolio companies. Accomplice's investment philosophy is centered on being high conviction, concentrated, and patient investors, dedicated to helping founders build successful, market-leading companies​.

Accuitive Medical Ventures (AMV) is a Duluth, Georgia-based venture capital firm founded in 2003, focused exclusively on early-stage medical device and healthcare technology investments. With $230 million in committed capital and offices in Palo Alto, Atlanta, Rochester, and Fernandina Beach, AMV is led by six managing directors: Gerard van Hamel Platerink, John Deedrick, Charlie Larsen, Mike Partsch, Steve Waite, and Tom Weldon. The firm invests $1 million to $10 million at seed through Series B stages, leading rounds across a portfolio of 86 companies. The portfolio has produced 3 IPOs and 10 acquisitions. Inogen, a portable oxygen concentrator company, listed on NASDAQ at a market cap of $70.6 million. NeuroStar, a transcranial magnetic stimulation device maker, IPO'd on NASDAQ in June 2018 at a $285 million valuation. Nevro, a spinal cord stimulation company, was acquired by Globus Medical in February 2025 for $250 million. Additional portfolio companies include POGO Automatic, AcuFocus (exited January 2023), and Sebacia. AMV takes a market-driven approach to investment, identifying revolutionary medical device and technology opportunities where clinical need is large and the path to reimbursement is clear. The firm's six-managing-director structure reflects deep specialization across cardiac, orthopedic, neurological, and ophthalmic device categories. Active board participation from managing directors with direct medical device operating experience distinguishes AMV's model from generalist healthcare VCs, providing founders with investors who understand the clinical, regulatory, and commercial complexities of device development from product conception through exit.

Ace Management Partners is a technology-driven investment firm specializing in high-potential pre-IPO companies across industries like AI, FinTech, and other disruptive technologies. Their thematic funds reflect a commitment to identifying transformative opportunities globally, with a focus on markets showing rapid innovation and growth. They prioritize transparency by integrating advanced technology and real-time data to provide investors with unparalleled insights and clarity in decision-making. Their strategy is bolstered by partnerships with market leaders who collectively have experience exceeding $30 billion in private company transactions. While their specific average check size isn’t publicly disclosed, they emphasize operational excellence, suggesting a proactive, well-calibrated investment approach. The team comprises experts passionate about innovation and fostering strategic partnerships, combining decades of private equity and venture capital expertise. With a strong base in New York, they leverage global market insights and local expertise to deliver exceptional results in the evolving pre-IPO landscape.

ACME Capital is a prominent venture capital firm based in San Francisco, specializing in early-stage investments in disruptive technologies and innovative business models. Founded in 2013 by Hany Nada, Shervin Pishevar, and Scott Stanford, the firm focuses on sectors such as healthcare, financial services, and space exploration. Their notable investments include high-profile companies like Uber, Slack, and DraftKings, demonstrating a knack for identifying and nurturing industry leaders. ACME Capital's investment strategy is centered on supporting visionary founders who are tackling large-scale challenges with groundbreaking solutions. They emphasize platform shifts and technology breakthroughs that promise significant societal benefits. The firm typically leads funding rounds and provides not just capital, but also strategic guidance and operational support to help startups scale effectively. Geographically, ACME Capital has a strong focus on the United States, but their portfolio also includes companies with a global reach. Their commitment to diversity and inclusion is reflected in their investment choices, with a significant portion of their portfolio companies led by underrepresented founders. The team at ACME Capital includes experienced partners like Brian Yee and Alexander Fayette, who bring a wealth of expertise and a hands-on approach to their investment process. Entrepreneurs looking to engage with ACME Capital are encouraged to present bold, transformative ideas that have the potential to disrupt massive markets and drive significant impact.

ACME Capital, founded in 2018 and headquartered in San Francisco, is an early-stage venture capital firm specializing in transformative technologies and business model innovations. They invest in deep tech, hardware, disruptive consumer products, enterprise solutions, fintech, health, and web3 sectors. Notable portfolio companies include IonQ, Braintrust, Cue Health, Astra, Uhnder, and Forte, which exemplify ACME’s commitment to pioneering advancements and societal benefits. ACME's strategy emphasizes partnering with founders from ideation through to IPO, offering not just capital but also strategic support and valuable industry connections. They favor investments in companies demonstrating significant market traction and a clear path to scalability. Their recent Fund IV and adjacent Opportunity Fund raised over $300 million, underscoring their robust position in the venture capital landscape. ACME is also dedicated to diversity and inclusion, with a substantial portion of their investments and team members representing historically underrepresented groups. Key team members include Co-founders Hany Nada and Scott Stanford, who bring extensive experience in venture capital and entrepreneurship, enhancing ACME’s ability to guide startups toward successful exits.

Acorn Pacific Ventures, founded in 2015, is a venture capital firm based in San Mateo, California. The firm focuses on early and growth-stage technology companies, with a particular emphasis on cross-border investments between the U.S. and Asia. Their portfolio spans industries like e-commerce, AI, fintech, and healthcare, including notable investments in Reap, a Hong Kong-based fintech company, and PopChill, an e-commerce fashion platform. Acorn Pacific is known for its strategic expertise in cross-border expansion, helping startups navigate both Silicon Valley and Asia-Pacific markets. The firm targets companies that leverage proprietary technology and tackle complex challenges in Industry 4.0 and global supply chain transformation. Their typical investment range varies, but they are active in funding rounds from seed to Series B. Led by Chih-Kai Cheng and a team of experienced partners, Acorn Pacific provides not only capital but also operational support to help companies scale. Their portfolio includes ventures like Nuohui Health, Avatar Medical, and Proglix, demonstrating their strong presence across various tech-driven sectors​.

Acre Venture Partners, founded in 2016 and based in Santa Monica, California, is a venture capital firm focusing on innovations in food and agriculture. Acre's diverse portfolio includes notable investments in companies like Meati Foods, which specializes in clean, fungi-based protein meats and raised $50M in a Series B round co-led by Acre. Mori is another significant investment, providing silk-based coatings for food protection to reduce waste and extend shelf life. Inari, a unicorn company developing advanced seed breeding technology, is valued at $1.5B. Spoiler Alert is a B2B marketplace helping food businesses manage surplus food, thus reducing waste. Agrofy is an online platform for farm equipment and infrastructure products. Acre's investment strategy emphasizes sustainability and technological innovation in agrifood technology. Recently, Acre closed its third fund at $140 million, targeting advancements in agricultural robotics, AI, and machine learning. This includes investments in companies like Bonsai Robotics and Farm-ng, focusing on automation in agriculture. Leveraging extensive experience and strategic partnerships, including advisory roles from industry experts like Lynda Deakin from IDEO and Chef David Chang, Acre drives growth and innovation within its portfolio companies. The firm supports startups from pre-seed to Series B stages, ensuring they have the necessary resources and strategic guidance to succeed in the evolving agrifood tech sector.

Acrew Capital is a venture capital firm founded in 2019 and headquartered in Palo Alto, California. The firm focuses on investing in companies across various stages, from early to growth stages, emphasizing diversity and transformative technology. Acrew Capital operates two primary funds: the Long Term View (LTV) fund, which targets early-stage investments, and the Diversify Capital Fund (DCF), which focuses on growth-stage companies. The LTV fund invests in early-stage companies, typically in the Seed to Series A stages, with check sizes ranging from $1 to $15 million. The DCF fund is designed for growth-stage investments, offering $10 to $20 million per investment. Acrew Capital's investment strategy prioritizes deep domain expertise, diverse perspectives, and long-term commitments to their portfolio companies. The firm's core thesis areas include financial services, cybersecurity, data, augmented reality, virtual reality, web 3.0, and cryptocurrency sectors. Acrew Capital's notable investments include companies like Eden Health, BlockFi, and CipherTrace. They have successfully exited several investments through mergers and acquisitions, demonstrating a strong track record in identifying and nurturing high-potential startups​. The leadership team at Acrew Capital is composed of experienced professionals like Lauren Kolodny, Mark Kraynak, and Asad Khaliq, who bring extensive experience in venture capital and entrepreneurship. The firm's commitment to diversity is reflected in its team composition and investment approach, with a significant portion of its leadership being women or people of color​.

Act One Ventures, established in 2016 and based in Los Angeles, California, focuses on investing in early-stage companies, particularly in pre-seed and seed rounds. The firm primarily invests in sectors like e-commerce infrastructure, vertical SaaS, and fintech. Act One Ventures is known for its commitment to diversity, with over 70% of its portfolio companies led by women founders and those from underrepresented backgrounds. Notable investments by Act One Ventures include Cartwheel, a logistics and delivery software company; Dragonboat, a product portfolio management platform; Clovers, a human resources technology firm using conversational intelligence to enhance hiring practices; and Time Study, an AI-driven productivity tool for healthcare and enterprise applications. Act One Ventures takes a hands-on approach, working closely with founders to provide strategic guidance and support, helping startups navigate the challenges of early-stage growth. The firm's typical investment ranges from $500K to $3 million, reflecting its focus on providing substantial early support to its portfolio companies.

ACT Venture Capital, based in Dublin, Ireland, is an early-stage venture capital firm founded in 1994. The firm focuses on investing in high-potential technology companies across sectors such as AI, machine learning, enterprise software, deep tech, healthcare, and energy & climate. ACT has completed over 70 investments and manages around €627 million across multiple funds. Notable companies in ACT Venture Capital's portfolio include Cubic Telecom, a global connectivity management company; Ekco, a leading provider of cloud services; and Deciphex, which develops software solutions for digital pathology. The firm also backs companies like Gridbeyond, which focuses on intelligent energy management systems, and Provizio, an automotive safety technology company. ACT Venture Capital recently launched its sixth fund, ACT VI, with an initial close of €140 million, aiming to invest in 35 companies across its targeted sectors. This fund supports startups from seed to expansion stages, with the capacity to invest up to €10 million per company. The firm has a strong track record of successful exits, including the acquisition of SilverCloud Health by Amwell, Decawave by Qorvo, and Corvil by Pico. The leadership team at ACT includes John Flynn, Debbie Rennick, and John O’Sullivan, who bring extensive experience and expertise to the firm, supporting their portfolio companies through strategic guidance and robust networks.

ACT Venture Partners is an Amsterdam-based venture capital firm focusing on early-stage investments in deep-tech and enabling technologies across Europe, with additional strong ties to the Turkish market. They target sectors such as AI, IoT, data analytics, and healthcare, investing primarily during Seed and Series A rounds. ACT aims to back technically strong founders who are pioneering disruptive, market-transforming solutions. Some notable companies in their portfolio include Picus Security, Carbon Health, Eatron, and Nextmol. The firm typically leads seed rounds with checks up to €1 million, often continuing to support portfolio companies in subsequent funding rounds. Their investment strategy emphasizes hands-on collaboration, providing not only financial backing but also mentorship, networking, and strategic advice to help startups achieve critical product-market fit and scale. The core team comprises experienced professionals with backgrounds in engineering, finance, and entrepreneurship. Key figures include managing partners Erhan Kılıçözlü and Okan Kara, who bring decades of experience in tech transfer, venture capital, and innovation management, contributing to ACT's reputation as a value-adding partner for startups. ACT's approach involves close engagement from initial funding through to growth stages, leveraging their extensive network across Europe and beyond.

Actio Capital Ventures (ACV) is a boutique pre-seed investment firm dedicated to fueling the growth of early-stage startups in retail, health, and consumer goods sectors. Founded by entrepreneurs Eric and Zulfukar, the firm invests at the pre-seed stage with ticket sizes ranging from 2,000 to 20,000 euros, positioning it as a micro-fund providing foundational capital to companies at the earliest stages of business formation. ACV operates across North America and Europe, with a portfolio comprising over 30 investments across health technology, e-commerce, retail, and consumer goods. The firm applies a personalized approach to each investment, carefully selecting startups based on growth potential and alignment of values and long-term vision. ACV builds ongoing relationships with portfolio companies rather than providing one-time capital injections, offering mentorship, guidance, and connections to industry experts through the formative phases of company development. ACV's micro-check model serves a genuine gap in the early-stage ecosystem: the space between friends-and-family capital and traditional seed rounds, where many promising entrepreneurs lack the network to access institutional venture support. By targeting retail, health, and consumer goods — industries where disruptive innovation tends to follow consumer behavior shifts rather than pure technology breakthroughs — ACV backs founders with domain expertise and market insight rather than exclusively technical backgrounds. The firm's operator-led approach reflects the founding team's own experience building companies from the ground up.

Action Potential Venture Capital (APVC) is a leading medical technology venture capital firm founded by GlaxoSmithKline (GSK) in 2013. The firm focuses on advancing bioelectronic medicines and enabling technologies. APVC is headquartered in Cambridge, Massachusetts, with additional offices in Scotts Valley, California. APVC invests in companies that leverage advances in hardware, computing, and material science to regulate neural or cellular activity, aiming to treat a range of chronic diseases. Notable portfolio companies include Cala Health, which develops non-invasive neuromodulation therapies for conditions like essential tremor; CVRx, known for its FDA-approved BAROSTIM NEO therapy for heart failure; and Neuspera Medical, which is developing minimally invasive neuromodulation therapies for overactive bladder. The firm takes a hands-on role on the boards of startups, providing strategic guidance and support. APVC has made 25 investments to date, with recent notable investments in Exo, which offers AI-enabled handheld ultrasound imaging, and MicroTransponder, which focuses on therapies for neurological conditions. APVC's investment approach emphasizes diversity and inclusion within the healthcare and entrepreneurial communities. The leadership team includes Imran Eba and Juan-Pablo Mas, who bring extensive experience in venture capital and biotechnology investments.

Activant Capital, founded in 2015, is a venture capital firm that focuses on investing in companies during critical growth phases. With headquarters in Greenwich, Connecticut, and additional offices in New York, Berlin, and Cape Town, the firm has over $1 billion in assets under management. Activant Capital invests in various sectors, including fintech, supply chain, e-commerce, retail technology, and health tech. The firm has a strong portfolio featuring companies such as Boom Supersonic, DEUNA, Deliverr, Current, Finix, and Forter. Boom Supersonic is developing a new generation of supersonic commercial airliners, while Deliverr provides rapid e-commerce fulfillment solutions. Forter specializes in fraud prevention for online retailers, and Finix offers payment infrastructure for businesses. Activant Capital is known for its thesis-driven approach, concentrating on commerce infrastructure technology that enhances efficiency across industries. Their investment strategy emphasizes partnering with high-growth companies to redefine commerce systems. They provide extensive operational support to their portfolio companies, assisting with organizational structure, hiring, go-to-market strategies, and commercial introductions. The firm has also achieved several notable exits, including Hybris, which was sold to SAP for $1.4 billion, and Deliverr, highlighting their ability to identify and support transformative companies. Activant’s approach is to remain long-term partners, with fund lives extending up to 15 years to support the ambitious growth of their portfolio companies.

Activate Venture Partners, formerly known as Milestone Venture Partners, is an early-stage venture capital firm founded in 1999 and based in New York City. The firm focuses on investing in high-growth technology companies, particularly those in the healthcare and enterprise software sectors. Their strategy emphasizes being the first institutional investor in startups, with over 85% of their portfolio companies receiving pre-revenue investments​. Notable investments in their portfolio include companies like Healthify, Diameter Health, and Cureatr, reflecting their strong focus on healthcare technology. Additionally, they have invested in technology firms like Canvs.ai and Cloudnexa, which provide services ranging from market research to AWS management. Activate Venture Partners typically leads seed and early-stage financing rounds with initial investments often below $5 million. They are known for their hands-on approach, offering strategic guidance and support to help startups scale effectively. The leadership team includes co-founders Edwin Goodman and Todd Pietri, along with partners like Glen Bressner and Don Yount. Their extensive experience and deep industry connections provide valuable insights and resources to the companies they invest in​.

Active Capital is a venture capital firm based in San Antonio, Texas, that focuses on leading seed-stage investments, primarily in B2B SaaS companies. Founded by Pat Matthews, Active Capital aims to support startups that are building cloud-based software and infrastructure with the potential to scale rapidly. The firm typically writes checks ranging from $500,000 to $2 million and prides itself on being highly involved with its portfolio companies, offering hands-on support to help them grow from seed to later stages. Active Capital is particularly active in markets outside of Silicon Valley, seeking to back talented entrepreneurs across the U.S. who are often overlooked by more geographically concentrated funds. Their portfolio includes notable companies like CallRail, LawnStarter, and Bestow, all of which are examples of scalable B2B solutions that align with their investment thesis​. The firm is committed to leading rounds, often taking a lead role in both investments and operational guidance. Active Capital prefers to work closely with founders who are building high-growth SaaS platforms, leveraging its extensive network of industry experts and fellow investors. With a focus on long-term partnerships, Active Capital is positioned as a strategic ally for early-stage companies that are ready to accelerate their market entry and growth.

Acumen is a pioneering impact investment firm dedicated to addressing poverty through a unique approach it calls “patient capital,” designed to fund social enterprises that serve the most marginalized populations. Since its inception in 2001 by Jacqueline Novogratz, Acumen has invested over $150 million across 150+ companies worldwide. Its portfolio spans essential sectors like clean energy, agriculture, healthcare, and education, all aimed at empowering low-income communities with sustainable solutions that can operate at scale. Acumen’s methodology combines financial investment with a strong emphasis on management and leadership support. By focusing on long-term growth rather than immediate returns, Acumen supports businesses in emerging markets like East and West Africa, India, Latin America, and the U.S., ensuring they grow in both impact and profitability. Some of their prominent initiatives, such as off-grid energy projects in sub-Saharan Africa and affordable healthcare solutions in South Asia, reflect their commitment to transforming critical services for underserved populations. In addition to financial investment, Acumen fosters a culture of moral leadership through Acumen Academy, which educates entrepreneurs and social innovators on creating impactful and inclusive businesses. This dual approach of investment and training allows Acumen to build a pipeline of leaders and companies equipped to drive systemic change. With an extensive global network and partners ranging from corporate foundations to local entrepreneurs, Acumen continually expands its reach, working tirelessly to reimagine the role of capital in tackling poverty.

Acumen America is a venture capital arm of Acumen, founded in 2016 with a mission to tackle systemic poverty and inequality in the U.S. by investing in entrepreneurs with bold, scalable solutions. Their focus spans three main sectors: health, workforce development, and financial inclusion. They back early-stage, mission-driven companies addressing challenges like healthcare access, financial instability, and career mobility, often being the first to write a check at the pre-seed or seed stage. Acumen America’s portfolio includes companies such as Esusu, which helps renters build credit, Flourish, providing mental health services for young adults, and Everytable, which makes nutritious food accessible to low-income communities. They prioritize overlooked founders, with 60% of their portfolio led by people of color and 44% by women. Their investment strategy centers on systems change, aiming to bring enduring impact to underserved communities by supporting entrepreneurs who can disrupt industries like healthcare and financial services. They work closely with their portfolio companies, providing not just capital but deep operational support to scale impactful solutions.

Ada Ventures is a London-based venture capital firm focused on supporting early-stage startups with a particular emphasis on diversity and inclusion. Founded by Check Warner and Matt Penneycard, Ada Ventures aims to back founders who are often overlooked and underfunded, targeting sectors like climate equity, economic empowerment, and healthy aging​. The firm typically makes initial investments of around £500,000 and has developed innovative deal-sourcing methods, including a scout network and angel investment programs to reach underrepresented communities. This approach has led to successful investments in companies such as Huboo, Organize, and MOONHUB. Ada Ventures' portfolio from its first fund has raised an aggregate of £100 million in additional funding from prominent firms like GV and Index Ventures. Ada Ventures recently launched its second fund, raising £41 million in the first close, demonstrating strong support from the investor community and its commitment to creating a more inclusive venture capital landscape.

Adams Street Partners, founded in 1972, is a global leader in private markets investment management, with over $60 billion in assets under management. Based in Chicago, the firm operates across North America, Europe, and Asia-Pacific, investing through strategies that include primary, secondary, growth equity, credit, and co-investments. Adams Street Partners is particularly known for its expertise in venture capital, private equity, and fund of funds strategies. The firm has a long history of venture capital investments, having been active in the space since the 1970s. Their venture capital portfolio focuses on innovative, high-growth sectors such as healthcare, AI, enterprise software, and fintech. Adams Street also manages dedicated funds for early-stage companies and emerging managers. The firm’s strategic investment approach is designed to generate strong, risk-adjusted returns over time by supporting companies through market cycles and downturns. Adams Street Partners continues to build on its reputation by backing both new startups and established companies, making significant contributions to technological and industrial advancements. With a focus on long-term growth and innovation, the firm remains a prominent player in global private equity and venture capital.

Adapt Ventures is an early-stage venture capital firm with a global focus, investing in founders who have bold visions in sectors like fintech, software, healthcare, and consumer products. The firm typically writes checks ranging from $100,000 to $500,000 at the pre-seed and seed stages, intentionally not leading rounds or taking board seats to give founders autonomy. Their portfolio includes companies like Sanas, Clara, and Wander, showcasing their commitment to transformative, high-impact startups. Founded by brothers Ammar and Mohammed Amdani, Adapt takes a collaborative approach, ensuring hands-on support for their portfolio companies through each growth phase. The firm is well-known for leveraging its extensive network to assist startups with business development, fundraising, and scaling into new markets. This founder-first philosophy, coupled with a high degree of engagement, sets them apart in the VC space. Adapt Ventures has offices in Miami, New York, and Dubai, reflecting their broad geographic reach. The team, which includes partners like Ezra Kebrab and Alan Chang, brings deep expertise in areas like fintech, proptech, and consumer brands, providing founders with the resources and insights needed to scale their companies rapidly. With a goal of investing in around 10 to 12 new companies each year, Adapt offers focused, high-value support to its portfolio, making them a go-to partner for early-stage entrepreneurs.

Adara Ventures, founded in 2005 and headquartered in Madrid, Spain, specializes in early-stage investments in deep tech companies, focusing on sectors like cybersecurity, data and applications, infrastructure, DevOps, components, and digital health. Managing around €200 million in assets, Adara has invested in 85 companies. Their portfolio includes notable companies such as Seedtag, Scalefast, and AlienVault. Seedtag, a leader in Contextual AI for the AdTech industry, is one of their standout investments. Adara led Seedtag's initial €1.5 million round and has supported the company through its significant growth and recent €250 million funding round led by Advent International. Adara has seen several successful exits, including AT&T Cybersecurity and PlayGiga, showcasing their ability to identify and nurture high-potential startups. They typically invest in seed, Series A, and Series B rounds, with check sizes ranging from $500,000 to $3 million. The Adara team includes experienced professionals like Managing Partners Alberto Gómez and Nicolas Goulet, and Partner Alberto Echeverri, who bring extensive expertise to support their portfolio companies' growth and success. Adara Ventures continues to play a significant role in the European venture capital landscape, particularly in Spain and Western Europe.

ADB Ventures is the venture capital arm of the Asian Development Bank (ADB), established in January 2020 as the ADB Ventures Financing Partnership Facility and headquartered in Metro Manila, Philippines. The firm pairs equity capital with ADB's deep regional insights and institutional networks to support early-stage companies with technology-enabled solutions that contribute to achieving the Sustainable Development Goals across Asia and the Pacific. ADB Ventures operates three principal funds: a Seed Fund of approximately 8 million euros, Investment Fund 1 of approximately $60 million (raised September 2020), and Investment Fund 2 of approximately 40 million euros. The firm invests up to $4 million in equity at pre-Series A to Series A stages, with seed capital also available for early-stage climate-focused companies. Sectors include clean energy and industry, sustainable mobility and supply chains, sustainable agriculture and food, circular economy and green materials, green finance, and inclusive communities. The portfolio spans over 60 companies operating in 18 or more developing markets, with notable investments including Skycatch and Fortuna. Co-investors include British International Investment and Alteria Capital. ADB Ventures' 17-year fund life in its flagship vehicle reflects a patient capital model appropriate for impact investing in markets where technology adoption and regulatory environments evolve on longer timescales than in developed markets. The firm's mission-driven mandate allows it to accept longer holding periods and take first-institutional-check risk in markets where commercial VCs typically will not deploy, making it a structurally important anchor investor in Asia-Pacific's emerging climate and fintech ecosystems.

AdBio Partners, previously known as Advent France Biotechnology, is a Paris-based venture capital firm specializing in early-stage investments within the life sciences sector. Established in 2016, AdBio Partners focuses on identifying and nurturing promising startups across Europe, particularly in France, Belgium, Spain, and Ireland. Their investment strategy is centered on therapeutics, supporting innovative biotech projects with high potential to address unmet medical needs. The firm is deeply integrated into the European life sciences ecosystem, collaborating closely with research institutions and technology transfer offices to transform groundbreaking scientific discoveries into viable businesses. AdBio Partners also plays an active role in the development of its portfolio companies, often co-founding and providing hands-on operational support to ensure their growth and success. Led by an experienced team of professionals with extensive backgrounds in science, medicine, and entrepreneurship, AdBio Partners has successfully attracted international VC syndicates, further strengthening its portfolio. Some notable companies backed by AdBio include DiogenX and ARTHEx Biotech.